Program
Clomiphene
Also written as “Antioxidants + Clomiphene Citrate”, “Clomiphene Citrate 50 mg” and “Clomiphene Citrate 100 mg”.
Its studies are mostly in Oligospermia · Anovulation · Infertility, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hamad Medical | 11 open or running | phase 4since Sep 29, 2026 | Sep 29, 2026 | Oct 15, 2027phase 4 · NCT07862725 |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 2since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Midwest Fertility Specialists | 10 open or running | no phasesince Oct 1, 2014 | Oct 1, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2005First study: phase 2 study in AnovulationNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT00213148 · 271 enrolled · United States
- Oct 1, 2014Midwest Fertility Specialists's first study: no phase study in InfertilityNew to Midwest Fertility SpecialistsMidwest Fertility Specialists · NCT02294773 · 13 enrolled · United States
- Sep 29, 2026Hamad Medical's first study: phase 4 study in OligospermiaNew to Hamad MedicalHamad Medical · NCT07862725 · 360 planned · Qatar
Ahead
- Oct 15, 2027Primary completion: phase 4 study in OligospermiaHamad Medical · NCT07862725
TargetBeta
“Estrogen receptor alpha modulator”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07862725Oligospermia · Qatar | 4 | Not yet recruiting | Hamad Medical | Oct 15, 2027 | 360 |
| NCT02294773Infertility · United States | – | Completed | Midwest Fertility Specialists | Sep 2015 | 13 |
| NCT00213148Anovulation · United States | 2 | Completed | Merck KGaA, Darmstadt, Germany | Dec 12, 2007 | 271 |
How it is read
Names in the registry
- “Antioxidants + Clomiphene Citrate”, 1 entry
- “Clomiphene Citrate 50 mg”, 1 entry
- “Clomiphene Citrate 100 mg”, 1 entry
- “Clomiphene”, 1 entry
Conditions, from the studies’ own filings
- Oligospermia, 1 study
- Anovulation, 1 study
- Infertility, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.